Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a…
ZUG, Switzerland, Sept. 1, 2025 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech company, is developing a novel treatment to…
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical…